Document:

Exhibit 4.21

Description
of Securities of Seelos Therapeutics, Inc.

The authorized capital stock of Seelos Therapeutics, Inc., a Nevada
corporation (the “Company”), consists of:

		·	240,000,000 shares of common stock, $0.001 par value per share (“Common Stock”); and

		·	10,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”).

Common Stock

		·	Voting Rights. Holders of Common Stock are entitled to one vote per share for the election of directors and on all other
matters that require stockholder approval. Holders of Common Stock do not have any cumulative voting rights.

		·	Liquidation Rights. Subject to any preferential rights of any outstanding Preferred Stock, in the event of the Company’s
liquidation, dissolution or winding up, holders of Common Stock are entitled to share ratably in the assets remaining after payment of
liabilities and the liquidation preferences of any outstanding Preferred Stock.

		·	No Preemptive or Redemption Rights. Shares of Common Stock do not carry any redemption rights or any preemptive or preferential
rights enabling a holder to subscribe for, or receive shares of, any class of Common Stock or any other securities convertible into Common
Stock.

		·	Dividend Rights. Holders of Common Stock shall be entitled to receive dividends if, as and when declared by the Company’s
Board of Directors (the “Board”) in accordance with applicable law.

		·	Anti-Takeover Provisions. See the below section titled “Anti-Takeover Effects of Nevada Law and Provisions of
the Company’s Articles of Incorporation and Bylaws”.

Listing

The Common Stock is listed on the Nasdaq Capital Market under the
symbol “SEEL.”

Preferred Stock

Under the Company’s Amended and Restated Articles of Incorporation,
as amended (the “Articles of Incorporation”), the Board has the authority, without further action by the stockholders,
to designate one or more series of Preferred Stock and to fix the voting powers, designations, preferences, limitations, restrictions
and relative rights granted to or imposed upon the Preferred Stock, including dividend rights, conversion rights, voting rights, rights
and terms of redemption, liquidation preference and sinking fund terms. Any or all of these may be preferential to or greater than the
rights of the Common Stock. Of the Company’s authorized Preferred Stock, 1,000,000 shares have been designated as Series A Junior
Participating Preferred Stock, 800 shares have been designated as Series B 8% Cumulative Convertible Preferred Stock, and 600 shares have
been designated as Series C 6% Cumulative Convertible Preferred Stock. The Company currently has no outstanding shares of Preferred Stock.

 

    	 

	 

    

 

The Board may authorize the issuance of Preferred Stock with voting
or conversion rights that could adversely affect the voting power or other rights of the holders of shares of Common Stock. The issuance
of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in control of the Company and may adversely affect the market price
of the Common Stock and the voting and other rights of the holders of shares of Common Stock.

The Board may specify the following characteristics of Preferred
Stock:

		·	The designation and stated value, if any, of the class or series of Preferred Stock;

		·	The number of shares of the class or series of Preferred Stock offered, and the liquidation preference, if any, per share;

		·	the dividend rate(s), period(s) or payment date(s) or method(s) of calculation, if any, applicable to the class or series of Preferred
Stock;

		·	whether dividends, if any, are cumulative or non-cumulative and, if cumulative, the date from which dividends on the class or series
of Preferred Stock will accumulate;

		·	the provisions for a sinking fund, if any, for the class or series of Preferred Stock;

		·	the provision for redemption, if applicable, of the class or series of Preferred Stock;

		·	the terms and conditions, if applicable, upon which the class or series of Preferred Stock will be convertible into Common Stock,
including the conversion price or manner of calculation and conversion period;

		·	voting rights, if any, of the class or series of Preferred Stock;

		·	the relative ranking and preferences of the class or series of Preferred Stock as to dividend rights and rights, if any, upon the
liquidation, dissolution or winding up of the Company’s affairs;

		·	any limitations on issuance of any class or series of Preferred Stock ranking senior to or on a parity with the class or series of
Preferred Stock as to dividend rights and rights, if any, upon liquidation, dissolution or winding up of the Company’s affairs;
and

		·	any other specific terms, preferences, rights, limitations or restrictions of the class or series of Preferred Stock.

Warrants

As of December 31, 2021, the Company had outstanding warrants to
purchase [●] shares of Common Stock as follows:

		·	warrants to purchase an aggregate of 8,386 shares with an exercise price of $52.50 per share, all of which are currently exercisable
(subject to certain beneficial ownership limitations) and expire on April 20, 2022, all of which shall be automatically exercised on a
“cashless” basis upon expiration if the fair market value of the Common Stock is greater than the exercise price of the warrants
on the expiration date of the warrants;

		·	warrants to purchase an aggregate of 81,587 shares with an exercise price of $46.50 per share, all of which are currently exercisable
(subject to certain beneficial ownership limitations) and expire on May 17, 2022, all of which shall be automatically exercised on a “cashless”
basis upon expiration if the fair market value of the Common Stock is greater than the exercise price of the warrants on the expiration
date of the warrants;

 

    	 
    2

	 

    

 

		·	warrants to purchase an aggregate of 11,338 shares with an exercise price of $12.60 per share, all of which are currently exercisable
and expire on January 12, 2023;

		·	a warrant to purchase an aggregate of 916 shares with an exercise price of $21.30 per share, which is currently exercisable and expires
on January 12, 2023;

		·	warrants to purchase an aggregate of 2,037 shares with an exercise price of $21.30 per share, which are currently exercisable (subject
to certain beneficial ownership limitations) and expire on January 12, 2023;

		·	warrants to purchase an aggregate of 3,647 shares with an exercise price of $21.30 per share, all of which are currently exercisable
(subject to certain beneficial ownership limitations) and expire on March 3, 2023;

		·	warrants to purchase an aggregate of 11,081 shares with an exercise price of $12.60 per share, all of which are currently exercisable
and expire on March 3, 2023;

		·	warrants to purchase an aggregate of 11,836 shares with an exercise price of $18.75 per share, all of which are currently exercisable
(subject to certain beneficial ownership limitations) and expire on March 28, 2023;

		·	warrants to purchase an aggregate of 80,008 shares with an exercise price of $15.00 per share, all of which are currently exercisable
(subject to certain beneficial ownership limitations) and expire on May 17, 2023;

		·	warrants to purchase an aggregate of 7,668 shares with an exercise price of $10.125 per share, all of which are currently exercisable
(subject to certain beneficial ownership limitations) and expire on March 25, 2024, all of which shall be automatically exercised on a
“cashless” basis upon expiration if the fair market value of the Common Stock is greater than the exercise price of the warrants
on the expiration date of the warrants;

		·	warrants to purchase an aggregate of 646 shares with an exercise price of $387.00 per share, all of which are currently exercisable
and expire on October 17, 2024, all of which shall be automatically exercised on a “cashless” basis upon expiration if the
fair market value of the Common Stock is greater than the exercise price of the warrants on the expiration date of the warrants;

		·	warrants to purchase an aggregate of 510 shares with an exercise price of $492.00 per share, all of which are currently exercisable
and expire on July 23, 2025, all of which shall be automatically exercised on a “cashless” basis upon expiration if the fair
market value of the Common Stock is greater than the exercise price of the warrants on the expiration date of the warrants;

		·	a warrant to purchase an aggregate of 115,000 shares with an exercise price of $9.00 per share, which is currently exercisable (subject
to certain beneficial ownership limitations) and expires on March 25, 2024, which shall be automatically exercised on a “cashless”
basis upon expiration if the fair market value of the Common Stock is greater than the exercise price of the warrants on the expiration
date of the warrant;

		·	a warrant to purchase an aggregate of 89,239 shares with an exercise price of $12.00 per share, which is currently exercisable and
expires on March 25, 2024, which shall be automatically exercised on a “cashless” basis upon expiration if the fair market
value of the Common Stock is greater than the exercise price of the warrant on the expiration date of the warrant;

 

    	 
    3

	 

    

 

		·	Series A warrants to purchase an aggregate of 909,672 shares with an exercise price of $0.2957 per share, all of which are currently
exercisable (subject to certain beneficial ownership limitations) and expire on January 31, 2024;

		·	warrants to purchase an aggregate of 2,237,500 shares with an exercise price of $1.78 per share, all of which are currently exercisable
(subject to certain beneficial ownership limitations) and expire on August 28, 2023; and

		·	warrants to purchase an aggregate of 6,648,750 shares with an exercise price of $0.84 per share, which became exercisable on March
9, 2021 (subject to certain beneficial ownership limitations) and expire on March 9, 2026.

All of the outstanding warrants contain provisions for the adjustment
of the exercise price in the event of stock dividends, stock splits or similar transactions. In addition, certain of the warrants contain
a “cashless exercise” feature that allows the holders thereof to exercise the warrants without a cash payment to the Company
under certain circumstances. Certain of the warrants also contain provisions that provide certain rights to warrantholders in the event
of a fundamental transaction, including a merger or consolidation with or into another entity, such as:

		·	the right to receive the same amount and kind of consideration paid to the holders of Common Stock in the fundamental transaction;

		·	the right to require the Company or a successor entity to purchase the unexercised portion of certain warrants at the warrant’s
respective fair value using the Black Scholes option pricing formula; or

		·	the right to require the Company or a successor entity to redeem the unexercised portion of certain warrants for the same consideration
paid to holders of Common Stock in the fundamental transaction at the warrant’s respective fair value using the Black Scholes option
pricing formula.

Convertible Promissory Notes

As of December 31, 2021, the Company had outstanding convertible
promissory notes in an aggregate principal amount of $22,221,687.74, as follows:

		·	a convertible promissory note (as amended) in an initial principal amount of $22,000,000, which was issued on November 23, 2021 and
is convertible into up to 3,666,666 shares of Common Stock any time after August 23, 2022 and matures on November 23, 2024;

		·	a convertible promissory note in an initial principal amount of $110,843.87, which was issued on December 2, 2021 and matures on December
2, 2024; and

		·	a convertible promissory note in an initial principal amount of $110,843.87, which was issued on December 2, 2021 and matures on December
2, 2024.

Each of the outstanding convertible promissory notes provides that,
commencing on the nine month anniversary of the date of issuance of the applicable note, the holder of such note may convert any portion
of the then-outstanding principal amount into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits,
reverse stock splits, stock dividends and similar transactions. Beginning on the one year anniversary of the date of issuance of each
convertible promissory note, the applicable note will amortize in twenty-four monthly installments equal to the quotient of (i) the then-outstanding
principal amount of such note,

 

    	 
    4

	 

    

 

divided by (ii) the number of months remaining until the maturity
date of such note. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or
a combination of both. In addition, commencing on the last business day of the first month following the one year anniversary of the
date of issuance of each convertible promissory note, the Company will pay, on a monthly basis, all interest that has accrued and remains
unpaid on the then-outstanding principal amount of such note. Any portion of an amortization payment or interest payment that is paid
in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common
Stock during the 20 trading days prior to the date of issuance of the shares.

Anti-Takeover Effects of Nevada Law and Provisions of the Company’s
Articles of Incorporation and Bylaws

Certain provisions of Nevada law and the Articles of Incorporation,
and the Company’s Amended and Restated Bylaws, as amended (the “Bylaws”), could make the following more
difficult:

		·	acquisition of the Company by means of a tender offer;

		·	acquisition of the Company by means of a proxy contest or otherwise; or

		·	removal of the Company’s incumbent officers and directors.

These provisions, summarized below, could have the effect of discouraging
certain types of coercive takeover practices and inadequate takeover bids. These provisions may also encourage persons seeking to acquire
control of the Company to first negotiate with the Board.

Classified Board. The Articles of Incorporation provide
that the Board is to be divided into three classes, as nearly equal in number as possible, with directors in each class serving three-year
terms. This provision may have the effect of delaying or discouraging an acquisition of the Company or a change in the Company’s
management.

Filling Vacancies. The Articles of Incorporation provide
that newly created directorships resulting from any increase in the authorized number of directors or any vacancies in the Board resulting
from death, resignation, retirement, disqualification, removal from office or other cause shall, unless otherwise provided by law or resolution
of the Board, be filled only by a majority of the directors then in office, though less than a quorum. The directors so chosen shall hold
office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which they have been chosen
expires.

Removal. The Bylaws and the Nevada Revised Statutes
(“NRS”) provide that any director may be removed from the Board by the vote or written consent of stockholders
representing not less than two-thirds of the voting power of the issued and outstanding shares entitled to vote.

Requirements for Advance Notification of Stockholder Nominations
and Proposals. The Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates
for election as directors, other than nominations made by or at the direction of the Board.

    	 
    5

	 

    

 

Special Meetings of the Stockholders. The Bylaws
provide that special meetings of the stockholders may be called by the Chair of the Board or the Company’s President, or by the
Board acting pursuant to a resolution adopted by the total number of authorized directors, whether or not there exist any vacancies in
previously authorized directorships.

No Cumulative Voting. The Articles of Incorporation
and the Bylaws do not provide for cumulative voting in the election of directors.

Undesignated Preferred Stock. The authorization of
undesignated Preferred Stock in the Articles of Incorporation makes it possible for the Board to issue Preferred Stock with voting or
other rights or preferences that could impede the success of any attempt to change control of the Company. These and other provisions
may have the effect of deferring hostile takeovers or delaying changes in control or management of the Company.

Amendment of Charter Provisions. The amendment of
any of the above provisions set forth in the Articles of Incorporation, except for the provision making it possible for the Board to issue
undesignated Preferred Stock, would require approval by a stockholder vote by the holders of at least 66-2/3% of the voting power of all
the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors.

In addition, the NRS contain provisions governing the acquisition
of a controlling interest in certain Nevada corporations. Nevada’s “acquisition of controlling interest” statutes (NRS
78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling interest in certain Nevada corporations.
These “control share” laws provide generally that any person that acquires a “controlling interest” in certain
Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore
such voting rights. These laws will apply to the Company as of a particular date if the Company were to have 200 or more stockholders
of record (at least 100 of whom have addresses in Nevada appearing on the Company’s stock ledger at all times during the 90 days
immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation, unless the Company’s
articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These
laws provide that a person acquires a “controlling interest” whenever a person acquires shares of a subject corporation that,
but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third,
(2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election
of directors. Once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold
and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest
become “control shares” to which the voting restrictions described above apply. These laws may have a chilling effect on certain
transactions if the Articles of Incorporation or Bylaws are not amended to provide that these provisions do not apply to the Company or
to an acquisition of a controlling interest, or if the Company’s disinterested stockholders do not confer voting rights in the control
shares.

    	 
    6

	 

    

 

Nevada’s “combinations with interested stockholders”
statutes (NRS 78.411 through 78.444, inclusive) provide that specified types of business “combinations” between certain Nevada
corporations and any person deemed to be an “interested stockholder” of the corporation are prohibited for two years after
such person first becomes an “interested stockholder” unless the corporation’s board of directors approves the combination
(or the transaction by which such person becomes an “interested stockholder”) in advance, or unless the combination is approved
by the board of directors and sixty percent of the corporation’s voting power not beneficially owned by the interested stockholder,
its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions may apply even after such two-year period.
For purposes of these statutes, an “interested stockholder” is any person who is (1) the beneficial owner, directly or indirectly,
of 10% or more of the voting power of the outstanding voting shares of the corporation, or (2) an affiliate or associate of the corporation
and at any time within the two previous years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of
the then- outstanding shares of the corporation. The definition of the term “combination” is sufficiently broad to cover most
significant transactions between a corporation and an “interested stockholder”. These laws generally apply to Nevada corporations
with 200 or more stockholders of record. However, a Nevada corporation may elect in its articles of incorporation not to be governed by
these particular laws, but if such election is not made in the corporation’s original articles of incorporation, the amendment (1)
must be approved by the affirmative vote of the holders of stock representing a majority of the outstanding voting power of the corporation
not beneficially owned by interested stockholders or their affiliates and associates, and (2) is not effective until 18 months after the
vote approving the amendment and does not apply to any combination with a person who first became an interested stockholder on or before
the effective date of the amendment. The Company has not made such an election in its original articles of incorporation or in its Articles
of Incorporation and the Company has not amended its Articles of Incorporation to so elect.

Further, NRS 78.139 also provides that directors may resist a change
or potential change in control of the corporation if the board of directors determines that the change or potential change is opposed
to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies
pursuant to NRS 78.138(4).

 

    	 
    7Exhibit 4.22

 

AMENDMENT TO CONVERTIBLE
PROMISSORY NOTE 

This Amendment (this “Amendment”)
to that certain Convertible Promissory Note No. 1, issued on November 23, 2021 (the “Note”), in the principal
amount of $22,000,000 and due November 23, 2024, by Seelos Therapeutics, Inc., a Nevada corporation (the “Company”),
to Lind Global Asset Management V, LLC, a Delaware limited liability company (together with its successors and representatives, the “Holder”),
is made as of December 10, 2021, by and between the Company and the Holder.

RECITALS

Whereas,
the Company issued the Note to the Holder pursuant to that certain Securities Purchase Agreement, dated as of November 23, 2021, by and
among the Company and the Holder (the “Securities Purchase Agreement”) (as the same may be amended from time
to time);

Whereas,
the staff of The Nasdaq Stock Market LLC has requested that the Company and the Holder amend certain provisions of the Note to ensure
compliance with Nasdaq Listing Rule 5635(d);

Whereas,
the Company and the Holder desire to amend certain provisions of the Note as set forth herein; and

Whereas,
pursuant to Section 5.8 of the Note, the Note may be amended by an instrument in writing signed by the Company and the Holder.

Now,
Therefore, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

1.                 
Section 3.8. Section 3.8 of the Note is hereby amended and restated in its entirety to read as follows:

“3.8Stock
Exchange Limitation. Notwithstanding anything to the contrary in this Note, unless the Company obtains a stockholder approval contemplated
by Nasdaq Listing Rule 5635(d) with respect to the issuance of shares of Common Stock pursuant to the Purchase Agreement in excess of
the limitations imposed by such rule, in no event will the sum of: (i) the aggregate number of Repayment Shares and Conversion Shares
issued under this Note, plus (ii) the aggregate number of Repayment Shares and Conversion Shares issued under any other “Note”
as defined in the Purchase Agreement and all other Securities Purchase Agreements entered into with other parties on or around the date
of the Purchase Agreement pursuant to which the Company issues notes similar to this Note (the Purchase Agreement and all such other Securities
Purchase Agreements, the “Purchase Agreements”), plus (iii) the number of First Closing Shares issued pursuant to the
Purchase Agreements and all other Purchase Agreements (as adjusted for stock splits, recapitalizations and similar transactions), exceed
20,478,005 shares in the aggregate (as adjusted for stock splits, recapitalizations and similar transactions). If the Company is not able
to issue shares upon a conversion of this Note as a result of the operation of the preceding sentence, then any portion of this Note that
cannot be so converted shall remain outstanding until repaid by the Company in cash.”

 

    	

	 

    

  

2.                 
Effectiveness. This Amendment is effective as of the date hereof. From and after the effectiveness of this Amendment, each
reference to “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference
and each reference to “this Note” and each other similar reference contained in the Note shall refer to the Note, as amended
hereby. Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver
of or otherwise affect the rights and remedies of the parties under the Note, and shall not alter, modify, amend or in any way affect
any of the terms, conditions, obligations, covenants or agreements contained in the Note.

3.                 
Governing Law. This Amendment shall be governed by and construed in accordance with the Laws
of the State of New York, without reference to principles of conflict of laws or choice of laws.

4.                 
Counterparts. This Amendment may be executed in two identical counterparts, both of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. Signature
pages delivered by facsimile or e-mail shall have the same force and effect as an original signature.

[Signature Page Follows]

 

 

 

 

 

 

    	2

	 

    

  

The parties hereto have
executed this Amendment to Convertible Promissory Note as of the date first written above.

THE company:

 

SEELOS THERAPEUTICS,
INC.

 

 

By:/s/ Raj Mehra, Ph.D.

Name: Raj Mehra, Ph.D.

Title: President and Chief Executive Officer

 

 

THE HOLDER:

LIND GLOBAL ASSET MANAGEMENT V, LLC

 

 

By:/s/ Jeff Easton

Name: Jeff Easton

Title: Managing Member

 

 

 

 

 

 

 

 

 

[Signature Page
to Amendment to Convertible Promissory Note]

 

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]